Healthcare / Medical DevicesNasdaqGM
$27.86
+1.53 (+5.81%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-103.6M · quality 69.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
33/100
D
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$1.6B
P/E
N/A
•EV/EBITDA
N/A
•ROE
-26.1%
↓Gross Margin
63.7%
↑Debt/Equity
0.21
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2020–2025 · 5 años de histórico normalizado
Revenue CAGR
+109.0%
FCF CAGR
—
FCF margin
-18.9%
FCF / Net income
0.61x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $308.1M · net income $-95.6M · FCF $-58.3M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Income Statement | |||||||
| Revenue | $308.1M | $308.1M | $224.5M | $136.2M | $75.0M | $34.5M | $7.7M |
| Net Income | $-95.6M | $-95.6M | $-91.4M | $-105.9M | $-87.2M | $-59.9M | $-53.0M |
| EBITDA | $-85.4M | $-85.4M | $-81.6M | $-98.0M | $-79.1M | $-50.8M | $-44.9M |
| EPS | -1.72 | -1.72 | -1.75 | -2.24 | -1.96 | -3.63 | -14.47 |
| Gross Margin | 63.7% | 63.7% | 61.1% | 52.2% | 49.4% | 46.0% | -16.3% |
| Operating Margin | -33.7% | -33.7% | -43.0% | -80.2% | -107.6% | -157.1% | -619.4% |
| Net Margin | -31.0% | -31.0% | -40.7% | -77.8% | -116.2% | -173.6% | -687.0% |
| Balance Sheet | |||||||
| Debt/Equity | 0.21 | 0.21 | 0.20 | 0.28 | 0.39 | 0.19 | -0.24 |
| Current Ratio | 6.73 | 6.73 | — | — | — | — | — |
| Cash Flow | |||||||
| Free Cash Flow | $-58.3M | $-58.3M | $-103.6M | $-133.2M | $-83.0M | $-57.9M | $-48.6M |
| Returns | |||||||
| ROE | -26.1% | -26.1% | -22.7% | -37.7% | -44.2% | -22.4% | 29.0% |
| Valuation | |||||||
| P/B | 4.23 | 4.23 | 10.92 | 6.87 | 8.87 | — | — |
| Growth & Yield | |||||||
| Revenue Growth | 37.2% | 37.2% | 64.8% | 81.6% | — | 346.7% | — |
| EPS Growth | 1.7% | 1.7% | 21.9% | -14.3% | — | 74.9% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-52.0%
Start / end P/E
n/dx → n/dx
EPS bridge
-1.75 → -1.72
Residual
-52.0%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.